What Is GB-115?
GB-115 is an anxiolytic (anti anxiety) dipeptide originally developed in Russia and marketed there as Ranquilon. It’s a CCK (cholecystokinin) related compound that’s been researched for anxiety reduction without the classic “benzo haze” profile people worry about.
Mechanisms of Action
CCK pathway modulation: GB-115 is described in the research literature as a cholecystokinin receptor antagonist, a pathway that has been linked with anxiety like signaling in multiple models.
Anxiolytic signaling without tolerance patterns: In rodent work, GB-115 maintained anxiolytic effects across repeated dosing, contrasting with patterns often seen with benzodiazepines.
Immunomodulatory effects in preclinical models: Separate animal data reports “immunocorrecting” activity and stimulation of some immune parameters in specific mouse models.
Benefits
Anxiety reduction: In a small clinical sample reported in a European Psychiatry abstract, median Hamilton Anxiety (HAM A) scores fell from 22 to 5 over 21 days, which is about a 77% reduction from baseline.
Fatigue improvement: In that same report, fatigue severity scores also decreased over the same period.
Less “withdrawal style” concern vs classic sedatives (preclinical): Rodent data specifically evaluated tolerance/withdrawal type effects and reported no tolerance or withdrawal syndrome signals under the conditions tested.
Dosing
Common clinical discussion used 6 mg daily for 21 days.
Safety Profile
GB-115 is often described as well tolerated but the public human data that’s easily accessible is limited.
Preclinical work reports no tolerance development and no withdrawal syndrome in the model tested.
Human safety details (rates of side effects, labs, discontinuations) are not richly reported in the abstract level source, so safety confidence is still constrained.
Stacking
Anti Anxiety and Stress Relief Stack
GB-115
Selank
Oxytocin
Disclaimer: The information provided is for educational purposes only and is not medical advice. Not for human consumption.
